Envestnet Asset Management
SCPH

Envestnet Asset Management’s scPharmaceuticals SCPH Stock Holding History

Envestnet Asset Management’s Portfolio SCPH Stock Details SCPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-14,186
Closed -$92K – 4046
2022
Q3 		$92K Buy
+14,186
New +$75.8K ﹤0.01% 3750
2022
Q2 		– Sell
-10,228
Closed -$58K – 4052
2022
Q1 		$58K Sell
10,228
-2,654
-21% -$13K ﹤0.01% 3849
2021
Q4 		$65K Buy
12,882
+2,186
+20% +$12K ﹤0.01% 3794
2021
Q3 		$71K Buy
+10,696
New +$63.9K ﹤0.01% 3617

Other funds holding SCPH

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $44.3M AUM 34.55% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $5.65B AUM 61.31% 1-Year Est. Return

Envestnet Asset Management's SCPH Position: Q4 2022 in Review

Envestnet Asset Management sold out of scPharmaceuticals (SCPH) in Q4 2022, closing a stake of 14,186 shares — an estimated $92K sold.

Envestnet Asset Management first reported a position in SCPH in Q3 2021 and held it in 4 quarters. The position peaked at $92K in Q3 2022. 58 funds tracked by Wall St. Rank hold SCPH as of Q4 2022.

  • Envestnet Asset Management reported no remaining scPharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • Envestnet Asset Management sold 14,186 scPharmaceuticals shares in Q4 2022, an estimated $92K.
  • Envestnet Asset Management first reported a position in scPharmaceuticals in Q3 2021 and held it in 4 quarters.
  • Envestnet Asset Management's scPharmaceuticals position peaked at $92K in Q3 2022.
  • 58 funds tracked by Wall St. Rank held scPharmaceuticals as of Q4 2022.

Based on Envestnet Asset Management's 13F filing for Q4 2022, filed 7 Feb 2023.